Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features

RAINBO MMRd-GREEN is an international, multicenter, phase III randomised trial wherein adjuvant pelvic external beam radiotherapy combined with and followed by durvalumab for one year is compared to adjuvant pelvic external beam radiotherapy with or without chemotherapy.

Trial Details

NCT ID
NCT05255653
Phase
PHASE3
Sponsor
Leiden University Medical Center
Status
RECRUITING
Cancer Type
Uterine Cancer
Interventions
  • Pelvic external beam radiotherapy
  • Chemotherapy
  • Durvalumab
  • Vaginal brachytherapy
Locations (sample)
  • Antwerp, Belgium|51.22047,4.40026
  • Brussels, Belgium|50.85045,4.34878
  • Charleroi, Belgium|50.41136,4.44448
  • Mons, Belgium|50.45413,3.95229
  • Namur, Belgium|50.4669,4.86746

Key Eligibility Criteria

  • Inclusion Criteria of the overarching RAINBO program:
  • Histologically confirmed diagnosis of endometrial cancer (EC) of the following histotypes: endometrioid endometrial carcinoma, serous endometrial c…
  • Full molecular classification performed following the diagnostic algorithm described in WHO 2020 (5th Edition, IARC, Lyon, 2020)
  • TLH-BSO or TAH-BSO with or without lymphadenectomy or sentinel node biopsy, without macroscopic residual disease after surgery

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Cancer Trials on Trialify →